Frontage Holdings (HKSE:01521) FCF Margin % : 14.20% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Frontage Holdings's Free Cash Flow for the six months ended in Dec. 2023 was HK$146 Mil. Frontage Holdings's Revenue for the six months ended in Dec. 2023 was HK$1,027 Mil. Therefore, Frontage Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was 14.20%.

As of today, Frontage Holdings's current FCF Yield % is 5.66%.

The historical rank and industry rank for Frontage Holdings's FCF Margin % or its related term are showing as below:

HKSE:01521' s FCF Margin % Range Over the Past 10 Years
Min: -3.3 Med: 6.45 Max: 20.98
Current: 7.14

During the past 8 years, the highest FCF Margin % of Frontage Holdings was 20.98%. The lowest was -3.30%. And the median was 6.45%.

HKSE:01521's FCF Margin % is ranked better than
84.89% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs HKSE:01521: 7.14

Frontage Holdings FCF Margin % Historical Data

The historical data trend for Frontage Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings FCF Margin % Chart

Frontage Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

4.84

13.15

-3.30

5.75

7.15

Frontage Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial									10.21	3.09	8.16	-0.07	14.20

Competitive Comparison of Frontage Holdings's FCF Margin %

For the Biotechnology subindustry, Frontage Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Frontage Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frontage Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Frontage Holdings's FCF Margin % falls into.

Frontage Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Frontage Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	145.152	/	2029.416
	=	7.15 %

Frontage Holdings's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	145.825	/	1026.981
	=	14.20 %

Frontage Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Frontage Holdings (HKSE:01521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

FGHQF:USA

Address

700 Pennsylvania Drive, Exton, PA, USA, 19341

Website

https://www.frontagelab.com

Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines